- Home
- SGC vs AQST Comparison
SGC vs AQST Comparison
Compare SGC & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGC
- AQST
- Stock Information
- Founded
- SGC 1920
- AQST 2004
- Country
- SGC United States
- AQST United States
- Employees
- SGC N/A
- AQST N/A
- Industry
- SGC Apparel
- AQST Biotechnology: Pharmaceutical Preparations
- Sector
- SGC Consumer Discretionary
- AQST Health Care
- Exchange
- SGC Nasdaq
- AQST Nasdaq
- Market Cap
- SGC 155.7M
- AQST 272.9M
- IPO Year
- SGC N/A
- AQST 2018
- Fundamental
- Price
- SGC $10.74
- AQST $3.40
- Analyst Decision
- SGC Strong Buy
- AQST Strong Buy
- Analyst Count
- SGC 3
- AQST 6
- Target Price
- SGC $17.00
- AQST $10.67
- AVG Volume (30 Days)
- SGC 55.4K
- AQST 1.6M
- Earning Date
- SGC 08-05-2025
- AQST 08-05-2025
- Dividend Yield
- SGC 5.14%
- AQST N/A
- EPS Growth
- SGC N/A
- AQST N/A
- EPS
- SGC 0.45
- AQST N/A
- Revenue
- SGC $563,931,000.00
- AQST $54,228,000.00
- Revenue This Year
- SGC N/A
- AQST N/A
- Revenue Next Year
- SGC $4.31
- AQST $45.71
- P/E Ratio
- SGC $24.23
- AQST N/A
- Revenue Growth
- SGC 2.28
- AQST 5.29
- 52 Week Low
- SGC $9.11
- AQST $2.12
- 52 Week High
- SGC $20.75
- AQST $5.80
- Technical
- Relative Strength Index (RSI)
- SGC 61.32
- AQST 58.21
- Support Level
- SGC $9.99
- AQST $3.13
- Resistance Level
- SGC $10.56
- AQST $3.33
- Average True Range (ATR)
- SGC 0.38
- AQST 0.21
- MACD
- SGC 0.06
- AQST -0.03
- Stochastic Oscillator
- SGC 76.92
- AQST 46.94
About SGC Superior Group of Companies Inc.
Superior Group Of Companies Inc designs apparel products. The company's operating segment includes Branded Products; Healthcare Apparel and Contact Centers. It generates maximum revenue from the Branded Products segment. The Branded Products segment produce and sell customized merchandising solutions, promotional products and branded uniform programs to customers.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.